Genmab — Oktober 2025
-
Before you invest in the SPDR
Bloomberg 1-3 Month T-Bill ETF (the “Fund”), you may want to review the Fund’s prospectus and
statement of additional information, which contain more information about the Fund and the risks of investing in the Fund. The
Fund’s prospectus and statement of additional information dated October 31, 2024, are incorporated by reference into this
summary prospectus. You can find the Fund’s prospectus, statement of additional information and reports to shareholders, a -
to shareholders, as well
as other information about the Fund, online at https://www.ssga.com. -
Gentogen 15,44: Køb af Merus diversificerer Genmabs indtægter væk fra Darzalex-royalties mod en "wholly owned"-model med egne produkter. Med fire proprietære programmer (inkl. epcoritamab og nu petosemtamab) forventes flere lanceringer fra 2027, hvilket skal opveje Darzalex-tabene. Dermed udskyder den den effektive patent cliff til ca. 2035, hvor de nye assets udløber.
-
Ifølge ”ClinicalTrials” har Genmabs store studie med GEN1042 (NCT04083599) fået reduceret antallet af patienter/Enrollment fra Estimated 1.287 til Actual 350. Det var da noget af en reduktion! Study Design skulle være ændret, men jeg kan ikke umiddelbart se hvilke ændringer der er sket. Er der nogen der kan uddybe/ved mere om dette?
-
Bernstein og deres underperform udmelding! De har aldrig ramt Gen kursen. Så er det da en dejlig afbalancering,at UBS f.eks opjusterede til 2.700 den anden dag. Hvorvidt de så har ramt den, lader vi stå. Men de er nok meget langt fra så skævt på den som Bernstein.
-
Peto patent udløber 2036, men får ved FDA godkendelse 12 års eksklusivitet frem til 2039 hvis godkendt i 2027. Det kan forlænges op til i alt 14 år efter godkendelse. Så at regne med en ny patent cliff i 2025 er helt væk. Kan slet ikke få mit hoved rundt om en kurs på 1.015 med en PE 6 i 2028. Det siger meget om Berstein at det kun er 30% rabat ift peers.:D
-
FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in patients with haemophilia A https://www.sciencedirect.com/science/article/pii/S247503792500531X
-
Handelsbanken is making a change to its sector favorites within Healthcare, [..]. Danish Genmab is Handelsbanken's first choice in the sector, https://x.com/StockwatchDK/status/1976566474316865959
-
Åben artikel: Genmab accelererer biopharma-strategi: Merus er løftestang https://proinvestor.com/investornyt/1369829/oversigt-ny-udgave-af-ou-life-science-genmab-accelererer-biopharma-strategi-merus-er-loftestang
-
Tak for artiklen. Virkelig god. Og interessant, at den og omtalerr zenocutuzumab, som vist ellers ikke har været meget omtalt, så jeg søgte lige lidt. Se for eksmpel https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic
-
-
Godmorgen
-
Godmorgen
-
ESMO 2025 1121P - Rinatabart sesutecan (Rina-S
) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL
-01 https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=Rinatabart+ -
1166P - Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=tisotumab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind